The probiotic Clostridium butyricum strain MIYAIRI 588 (CBM588) improves response rates and overall survival in patients receiving immune checkpoint inhibitor (ICI) therapy for non-small cell lung cancer and metastatic renal cell carcinoma but the mechanism underlying this benefit remains unclear...Across the patient cohort, higher post-treatment frequencies of CD69+ Vδ2 T-cells were associated with improved survival and more favourable clinical outcomes. These findings provide a potential mechanism by which manipulation of the intestinal microflora might contribute to cancer prognosis through effects on immune effector cells with intrinsic anticancer properties.

5 days ago

Journal • IO biomarker

CD69 (CD69 Molecule)

Cdactin-O (CBM588)

A Phase 1b Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multiple Dose Safety and Tolerability Study of Daily Dosing of BL-001 for 12 Weeks in Adults with Obesity (ACTRN12626000061336)

P1, N=48, Active, not recruiting, Bloom Science Australia Pty Ltd | Not yet recruiting --> Active, not recruiting

6 days ago

Enrollment closed • Trial initiation date

KAN-004 for Immune-Related Diarrhea or Colitis (clinicaltrials.gov)

P1, N=21, Recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Initiation date: Oct 2025 --> Mar 2026 | Not yet recruiting --> Recruiting

8 days ago

Enrollment open • Trial initiation date

13d

RESIST-PTSD: Microbiome Modulation With Prebiotics in PTSD and Cirrhosis (clinicaltrials.gov)

P=N/A, N=30, Recruiting, Hunter Holmes Mcguire Veteran Affairs Medical Center | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Jun 2027

13 days ago

Trial completion date • Trial primary completion date

15d

MIYAIRI 588: CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (clinicaltrials.gov)

P1, N=36, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Feb 2027

15 days ago

Trial completion date • Trial primary completion date

Cdactin-O (CBM588)

19d

IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=162, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting

19 days ago

Enrollment open

Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)

The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator "WellBiome" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings. (clinicaltrials.gov)

P=N/A, N=80, Not yet recruiting, Hull University Teaching Hospitals NHS Trust

1 month ago

New trial • HEOR

SYN-004 Safety and Tolerability in Allo-HCT Subjects (clinicaltrials.gov)

P1/2, N=36, Active, not recruiting, Theriva Biologics, Inc. | Trial completion date: Dec 2026 --> Sep 2030 | Trial primary completion date: Dec 2025 --> Sep 2029

1 month ago

Trial completion date • Trial primary completion date

NUTRIBRAIN: Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER) (clinicaltrials.gov)

P=N/A, N=120, Recruiting, National Science and Technology Council, Taiwan

1 month ago

New trial

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis (clinicaltrials.gov)

P2, N=58, Recruiting, The University of Texas Health Science Center, Houston | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

1 month ago

Trial completion date • Trial primary completion date